Inhibrx Biosciences reported its financial results for the second quarter of 2025, showing a net loss of $28.654 million. This represents a significant improvement compared to the operating losses experienced prior to the May 2024 spin-off of INBRX-101.
Research and development expenses decreased to $22.267 million in Q2 2025 from $67.632 million in Q2 2024, reflecting the company's focused pipeline post-divestiture. General and administrative expenses also saw a substantial reduction to $6.422 million from $93.366 million in the prior year period.
The company reported license fee revenue of $1.300 million for the quarter. As of June 30, 2025, Inhibrx maintained a solid cash and cash equivalents balance of $186.567 million, supporting its ongoing clinical development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.